Pfizer Articles
ViiV Healthcare committed to Phase III development program for investigational once-daily HIV integrase inhibitor
22 July 2010
12 July 2010
US FDA approves Teva’s generic venlafaxine, the first copy version of Pfizer’s Effexor XR
30 June 2010
Pfizer withdraws leukemia drug Mylotarg from US Market on safety concerns and poor efficacy
22 June 2010
Early closing of apixaban trial on good results in AF sees Pfizer and Bristol-Myers Squibb shares rise
14 June 2010
ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai
7 June 2010
Wyeth withdraws European MA application for Brilence; AstraZeneca to provide more info to US FDA on Axanum
1 June 2010
US FDA warns of fracture risks with proton pump inhibitors; calls for class labeling change
26 May 2010
Pfizer signs deals with Indian drugmaker Strides Arcolab for generic cancer drugs and niche injectables
17 May 2010
Shareholder class action law suits launched against Pfizer over “illegal promotion” of drugs
17 May 2010
Pfizer adds to its PAH portfolio, acquiring global rights to Ergonex’ drug candidate terguride
13 May 2010
Pfizer discontinues Ph III trial of Sutent in advanced liver cancer as it fails versus Bayer’s Nexavar
26 April 2010
Pfizer and MMV aim to expand fight against malaria, providing drugs for pregnant women
23 April 2010
Impax now to co-promote Pfizer’s Lyrica; updates on APEX-PD trial; Pfizer in deal with Stemgent on reagents
16 April 2010
Brazil patent protection – could this be the end of Pfizer’s Viagra there?; Korea rules a against Lipitor patent
29 March 2010
Jury finds against Pfizer, calling for $142M in damages for drug fraud; Teva gets tentative OK for generic Argatroban
26 March 2010
UK’s NICE sets national standard for neuropathic pain drug treatments in non-specialist NHS settings; guidance on angina
25 March 2010
Pfizer and GlaxoSmithKline pledge long-term supply of pneumococcal vaccines to world's poorest countries at big discount
24 March 2010
Teva triumphs in battle for Ratiopharm, with a whopping 3.6 billion-euro offer seeing off Pfizer and Actavis
19 March 2010
Australian Judge rules against Merck & Co’s Vioxx, saying the pain drug is not fit for sale
5 March 2010
Medivation slumps as Alzheimer’s drug candidate Dimebon, partnered with Pfizer, disappoints in Ph III
4 March 2010
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
One cheer for Pfizer’s Fablyn
26 February 2010
Pfizer gets US FDA approval for Prevnar 13, a Wyeth drug with blockbuster sales outlook
25 February 2010
Use of statins does increases risk of diabetes, but only by 9%, says report in Lancet
19 February 2010
Targeted cancer drug market set to reach $51 billion by 2015, led by Pfizer; barriers to use of oral cancer drugs identified
19 February 2010
Combo Alzheimer's drug that delays nursing home admission would earn higher patient share in the USA than Europe
18 February 2010
Vernalis to re-acquire EU frovatriptan royalties; Isogenica gains rights to commercialize drugs with MRSA potential
15 February 2010
Daiichi Sankyo gains US FDA approval of Benicar to treat high BP in children and adolescent; names new VP medical affairs
12 February 2010
Increasing competition from other biologics will continue to erode Enbrel's dominance in the psoriasis drug market, DR report concludes
12 February 2010
AstraZeneca gets wider US indications for Crestor; enters cancer drug development deal with UK charity
9 February 2010
Pfizer pushing medicines discount cards in emerging markets; partners in USA on care plans
9 February 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
The “new” Pfizer sees 4th qtr s2009 sales and profit rocket, but 2010 guidance disappoints
4 February 2010
Japanese drug major Astellas’ 3rd quarter net profit slumps 47% as Prograf hit by generic competition
3 February 2010
Pfizer debuts generic drug portfolio in the UK
3 February 2010
AstraZeneca to cut another 8,000 jobs as part of $1.8 billion cost-cutting program; unveils new R&D model
29 January 2010
Prioritized pipeline at “new” Pfizer marks important milestone for the company’s R&D organization
28 January 2010
Pfizer’s Sutent shows progress-free survival in patients with pancreatic neuroendocrine tumors
25 January 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Pfizer’s Wyeth awarded UK contract to supply Prevenar 13; but drops European OTC ibuprofen/diphenhydramine development
20 January 2010
Philippines seeks more voluntary drug price reductions
19 January 2010
Teva, Pfizer and EQT among final three bidders for Ratiopharm
19 January 2010
US FDA backs safety of Pfizer/Boehringer’s Spiriva HandiHaler; Pfizer admits EU investigation; gets sued over Chantix
15 January 2010
AstraZeneca gets novel anti-infective for Korean firm, AC Immune adds to Alzheimer’s portfolio with Russian drug
14 January 2010
“Extraordinary” drug price hikes identified by USA’s GAO
12 January 2010
Roche enters COPD sector with 400 million-plus-euro deal with Galapagos and antibody accord with AnaptysBio
12 January 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis
11 January 2010
World fibromyalgia syndrome market to grow at a CAGR of 9.2% for the next seven years, reaching $1.8 billion by 2015, forecasts Global Data
11 January 2010
Pfizer revives development of tremelimumab for advanced melanoma in deal with Debiopharm
8 January 2010
Pfizer makes another move into generics in deal with Strides Arcolab; enters into discovery accord with Ensemble
7 January 2010
European Commission OKs new IV form of Pfizer’s Revatio for pulmonary arterial hypertension
6 January 2010
Pfizer drops figitumumab in NSCLC on disappointing Ph III; FDA delays Prevnar 13 and rejects Basilea/J&J’s ceftobiprole for cSSSI
4 January 2010
New state pharma company - ENFARMA - created in Ecuador
4 January 2010
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
